# Caris Life Sciences

**Source:** https://geo.sig.ai/brands/caris-life-sciences  
**Vertical:** Healthcare  
**Subcategory:** Precision Oncology  
**Tier:** Growth  
**Website:** carislifesciences.com  
**Last Updated:** 2026-04-14

## Summary

Caris Life Sciences provides comprehensive molecular profiling of tumors to guide cancer treatment decisions, with one of the largest oncology biomarker databases.

## Company Overview

Caris Life Sciences is a precision oncology company founded in 1998 and headquartered in Irving, Texas, that provides comprehensive molecular profiling tests used by oncologists to select personalized cancer treatments. The company's flagship test Molecular Intelligence analyzes tumors using whole transcriptome sequencing, whole exome sequencing, and protein expression to identify biomarkers that predict response to specific therapies including targeted drugs and immunotherapies. Caris has built one of the largest real-world oncology molecular databases, with profiles from hundreds of thousands of patient tumors that are used for research, drug development partnerships, and AI model training. The company serves oncologists, cancer centers, and pharmaceutical companies conducting biomarker-driven clinical trials. Caris has raised over $1B and operates CLIA-certified laboratory facilities in Phoenix and Irving. The company's database and AI capabilities have attracted partnerships with pharmaceutical companies seeking to identify patient populations most likely to respond to novel therapies. Caris positions itself at the intersection of clinical diagnostics and drug development infrastructure, generating value both from patient care and from the insights its large clinical database enables.

## Frequently Asked Questions

### What is Caris Life Sciences?
Caris Life Sciences provides comprehensive molecular tumor profiling tests that analyze cancer biomarkers using whole genome and transcriptome sequencing to help oncologists select the most effective personalized treatments for individual patients.

### What is Molecular Intelligence?
Molecular Intelligence is Caris's comprehensive tumor profiling test that combines whole transcriptome sequencing, whole exome sequencing, and protein expression analysis to generate a complete biomarker map of a tumor for treatment selection.

### How does Caris's database support drug development?
Caris has profiled hundreds of thousands of patient tumors, creating one of the largest real-world oncology molecular databases that pharmaceutical companies use to identify biomarkers, select clinical trial populations, and understand response patterns for novel cancer therapies.

### What does Caris' comprehensive molecular profiling test include?
Caris' molecular profiling analyzes a tumor's full DNA, RNA, and protein expression using next-generation sequencing, whole transcriptome sequencing, and protein expression testing, providing oncologists with a comprehensive molecular portrait to guide treatment decisions.

### How does Caris help oncologists select cancer therapies?
By identifying actionable mutations, biomarkers, and expression patterns in a patient's tumor, Caris helps oncologists match patients to FDA-approved targeted therapies, immunotherapies, and clinical trials most likely to benefit their specific molecular tumor profile.

### What is Caris Assure and how does it contribute to cancer research?
Caris Assure is the world's largest molecular tumor database, containing data from hundreds of thousands of profiled patients. Pharma companies, researchers, and Caris itself use this database to discover biomarkers, understand tumor biology, and design more effective clinical trials.

### How does Caris handle liquid biopsy (blood-based testing)?
Caris offers liquid biopsy testing that analyzes circulating tumor DNA (ctDNA) from a blood draw, enabling molecular profiling when a tissue biopsy is not feasible and providing a non-invasive option for monitoring treatment response and detecting recurrence.

### Does Caris work with pharma companies on clinical trial matching?
Yes, Caris partners with pharmaceutical and biotech companies to identify molecularly matched patients for clinical trials, improving trial enrollment efficiency and matching patients with experimental therapies suited to their tumor's specific biology.

## Tags

startup, healthtech, technology, analytics, platform, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*